344 results about "Isoindoline" patented technology

The present invention relates to compounds (I) possessing an indole moiety linked to an isoindoline moiety, to compounds having similar core structures, and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present invention further relates to methods of synthesising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by Factor B inhibition.

The present disclosure relates to compounds of Formula (I) and Formula (II) or salts, enantiomers, stereoisomers, solvates, isotope enriched analogs, prodrugs or polymorphs thereof, and uses thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds of formula (I) or salts, enantiomers, stereoisomers, solvates, isotope enriched analogs, prodrugs or polymorphs thereof as active ingredients and uses thereof. # imgabs0 #

The present invention relates to a pharmaceutical composition for oral administration, for example in the form of a tablet or a powder suitable to be filled into a capsule shell, comprising 2-(isoindolin-2-ylmethyl)-5-((1-(methylsulfonyl)- piperidin-4-yl)methoxy)-4H-pyran-4-one (I) or a pharmaceutically acceptable salt thereof as an active ingredient. Compound (I) or a pharmaceutically acceptable salt thereof is a selective inhibitor of CYP11A1 enzyme and is useful in the treatment of hormonally regulated diseases such as cancer including prostate cancer and breast cancer.

The present invention relates to pharmaceutical compound, and formulations comprising the compound, wherein the compound has a structure according to formula I or II: The compound and formulations are suitable for use as a medicament in the prevention or treatment of a disease or a disorder characterized by pericyte dysfunction, detachment and / or loss, in a therapeutic treatment for blood vessel stabilization, in a treatment of promoting, restoring or preserving pericyte attachment to blood vessels, and / or in a treatment of a vascular-associated disease in a patient.

The invention belongs to the technical field of synthesis of organic compounds, and particularly relates to a chiral synthesis method of spiro [cyclopenta [c] carbazole-1, 1 '-isoindoline]-3'-ketone compounds. The compound synthesized by the invention has an isoindolinone skeleton and a carbazole active fragment at the same time. The carbazole compound and the isoindolinone compound are successfully combined in a cyclization mode for the first time, and the chiral compound can be prepared. The invention provides a synthesis method of a chiral spiro [cyclopenta [c] carbazole-1, 1 '-isoindoline]-3'-ketone compound, which has the advantages of mild reaction conditions, green and environment-friendly catalyst, easiness in operation, few synthesis steps, easiness in purification and separation of products, capability of obtaining higher yield and high stereoselectivity, easiness in amplification of reaction, high yield, high yield and high yield, and is suitable for large-scale production of the chiral spiro [cyclopenta [c] carbazole-1, 1 '-isoindoline]-3'-ketone compound. And the method has a wide application prospect.

The invention relates to the technical field of epoxy resin, in particular to an optical epoxy resin molding compound and a preparation method and application thereof. The coating comprises the following components: a colorant, epoxy resin, an antioxidant, a curing agent and an auxiliary agent, the color agent comprises an ultraviolet absorbent and a blue light absorbent; the epoxy resin comprises triazine skeleton epoxy resin. The toner comprises an ultraviolet absorbent and a blue light absorbent, and the epoxy resin comprises triazine skeleton epoxy resin, so that light rays below 460 nm can be effectively shielded, the transmittance of light rays above 500 nm reaches 85% or above, and meanwhile, excellent high-temperature resistance is achieved; the ultraviolet absorbent comprises a triazine ultraviolet absorbent, and the blue light absorbent comprises a triazine derivative structure of an isoindolinone heterocyclic skeleton, so that the numerical value of 460 nm light transmittance / 500 nm light transmittance can be reduced to 0.5 or below.

Provided are compounds of formula (I) and formula (II) or salts, enantiomers, stereoisomers, solvates, isotopically enriched analogues, prodrugs, or polymorphs thereof, and uses thereof. Further provided are a pharmaceutical composition containing the compound of formula (I) as an active ingredient, or the salt, enantiomer, stereoisomer, solvate, isotopically enriched analogue, prodrug, or polymorph thereof, and a use thereof.

The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.

To provide a red photosensitive composition which enables formation of a film that is excellent in storage stability and has excellent resistance after low temperature heating.SOLUTION: A red photosensitive composition contains a coloring material (A), a resin (B) having an acidic group, a polymerizable compound (C), and a polymerization initiator (D), wherein the coloring material (A) contains a red coloring material (A1) and a yellow coloring material (A2), the red coloring material (A1) contains one or more kinds selected from the group consisting of C.I. pigment red 179 and C.I. pigment red 264, the yellow coloring material (A2) contains an isoindoline pigment, and the polymerization initiator (D) contains a polymerization initiator (D1) having absorption coefficient of light at a wavelength of 365 nm in propylene glycol monomethyl ether acetate of 5.0×103 L / mol cm or more.SELECTED DRAWING: None

The present disclosure relates to a compound represented by formula (I) or a salt, enantiomer, stereoisomer, solvate, polymorph thereof and a use thereof. The present disclosure also relates to pharmaceutical compositions comprising, as an active ingredient, the compound represented by formula (I) or the salt, enantiomer, stereoisomer, solvate, polymorph thereof, and a use thereof. In the present disclosure, the compounds designed and synthesized can effectively prevent or treat diseases or conditions related to celeblon protein, including tumors or cancers.

The invention belongs to the technical field of biological medicines, and particularly relates to a compound as shown in a formula (I), pharmaceutically acceptable salt, deuterated substance, stereoisomer, tautomer or a mixture of the pharmaceutically acceptable salt, the deuterated substance, the stereoisomer and the tautomer, and application of the compound as an IKZF1 and IKZF3 double-target immunomodulator.

Disclosed is a compound of Formula (I): or stereoisomers, tautomers, or salts thereof. Also disclosed are methods of using such compounds to decrease the levels of IKZF1-4 proteins; and pharmaceutical compositions comprising the compound. The compound is useful in the treatment of viral infections and proliferative disorders, such as cancer.

The application relates to a preparation method of an arylmethoxy isoindoline derivative and belongs to the field of pharmaceutical chemical industry. Specifically, a compound of formula III and a compound of formula II are reacted in an organic solvent in the presence of a reducing agent to generate a compound of formula I. A new preparation route of the arylmethoxy isoindoline derivative is provided, and the preparation route has high yield and high product purity.

The present invention relates to an isoindolinone derivative, a preparation method, a pharmaceutical composition and an application. The derivative is a compound of formula I or a pharmaceutically acceptable salt of the compound of formula I, wherein Ra is one of a substituted or unsubstituted aryl, a substituted or unsubstituted C1-C6 alkyl; Rb and Rc are each one of a substituted or unsubstituted C1-C6 alkyl. Compared with the prior art, the isoindolinone derivative in the present invention has a novel structure, has significant anti-cancer cell proliferation activity, and the activities of multiple compounds are superior to those of doxorubicin.

The application discloses a 3-(5-(aminomethyl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione derivative and a synthesis method and application thereof, and relates to a 3-(5-(aminomethyl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione derivative which is a compound with the following general formula (I): wherein R1 is selected from,,,,,,,,, and R2 is selected from,,, and. The compound can significantly inhibit the proliferation of leukemia, multiple myeloma, lymphoma, breast cancer, liver cancer and the like at a low dose (nanomole), can effectively degrade IKZF1, IKZF3, BRD4, GSPT1 and CK1 alpha, and has the prospect of being developed into an anti-tumor drug. The application solves the problem that the existing malignant hematological disease treatment drugs have a high safety risk.

The present disclosure provides a compound of Formula (I'): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and Ri are as defined herein, and methods of making and using same.

Disclosed are compounds of Formula (I) or a salt thereof, wherein Ring A is a carbon-linked ring; and Ring A, R1, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

A method for producing a furoic acid derivative may include an oxidation step of oxidizing a furfural derivative to obtain a furoic acid derivative in the reaction system of pH 3-12. A method for producing a furan derivative may include a decarboxylation step of decarboxylating a furoic acid derivative to obtain a furan derivative without using a catalyst, using an oxide of mono-to tri-valent transition metal as a catalyst, or using a high boiling point solvent. A method for producing a furan derivative may include the oxidation step of obtaining a furoic acid derivative and the decarboxylation step of obtaining a furan derivative. A method for producing a phthalocyanine derivative or an isoindoline derivative may include obtaining a phthalocyanine derivative or an isoindoline derivative from the furan derivative obtained by any one of the methods for producing a furan derivative.

The invention discloses a 1-oxo-isoindoline derivative with a structure as shown in a formula (I) and pharmaceutically acceptable salt, solvate, crystal form or stereoisomer thereof, the 1-oxo-isoindoline derivative can be used as a molecular glue degradation agent of GSPT1, has high degradation activity on GSPT1, and has good potential safety. The derivative can be used for degrading GSPTl, preparing drugs for treating diseases related to GSPTl activity and preparing antibody coupling degradation drugs. # imgabs0 #

The present invention belongs to the technical field of pharmaceutical intermediates, and specifically relates to a preparation method of 6-bromo-2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione. The preparation of 6-bromo-2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione uses 1-fluoronaphthalene as the starting material, and undergoes selective bromination, Oxone oxidation, and Ac2O dehydration and acid anhydride formation / amidation, a total of three steps of reactions to obtain the finished product. The preparation method provided by the present invention is scientifically and reasonably designed, and can achieve the safe preparation of 6-bromo-2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione with the characteristics of environmental protection and low cost.

The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and / or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and / or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting or blocking NUAK kinase, such as cancers and fibrosis.

The present invention relates to an isoindoline compound containing a phenylethoxyalkyleneamine structure, a conjugate thereof, and use thereof. The isoindoline compound containing a phenylethoxyalkyleneamine structure has a structure represented by formula (I). The conjugate thereof has a structure represented by formula (B). The compound of the present invention exhibits increased proliferation inhibition activity for cancer cells and a degradation effect on proteins such as GSPT1, demonstrating practical values.

Salts and solid forms of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a stereoisomer thereof, are disclosed. Compositions comprising and methods of using the salts and solid forms are also disclosed.

Provided are compounds of the structural Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with ALK.

The present disclosure relates to compounds of formula (I) or salts, enantiomers, stereoisomers, solvates, polymorphs thereof, and uses thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds of formula (I) or salts, enantiomers, stereoisomers, solvates, polymorphs thereof as active ingredients and uses thereof. A series of compounds designed and synthesized by the invention can be used for effectively preventing or treating diseases or symptoms related to the cerebron protein. # imgabs0 #

The present invention relates to pharmaceutical compounds and formulations comprising said compounds, wherein said compounds have the structure according to Formula I or II. The compounds and formulations are suitable for use as medicaments for the prevention or treatment of diseases or conditions characterized by percutaneous cell dysfunction, detachment and / or loss, for medical treatment for vascular stabilization, for treatment for promoting, restoring or maintaining attachment of percutaneous cells to blood vessels, and / or for the treatment of vascular-related diseases in patients. (I) (II)